186 related articles for article (PubMed ID: 30303650)
1. [EVALUATION OF CARDIOVASCULAR RISKS WITH THE USE OF MORPHOGENETIC KLOTHO PROTEIN IN PATIENTS WITH CHRONIC RENAL DISEASE].
Mukhin NA; Milovanova LY; Fomin VV; Kozlovskaya LV; Taranova MV; Androsova TV; Borisov AA
Klin Med (Mosk); 2017; 95(3):272-7. PubMed ID: 30303650
[TBL] [Abstract][Full Text] [Related]
2. [Decreased Serum Levels of Klotho Protein in Chronic Kidney Disease Patients: Clinical Imortance].
Milovanova LY; Mukhin NA; Kozlovskaya LV; Milovanov YS; Kiyakbaev GG; Rogova IV; Lebedeva MV; Androsova TV; Milovanova SY; Gil AY; Taranova MV
Vestn Ross Akad Med Nauk; 2016; 71(4):288-96. PubMed ID: 29297646
[TBL] [Abstract][Full Text] [Related]
3. [Role of the morphogenetic proteins FGF-23 and Klotho and the glycoprotein sclerostin in the assessment of the risk of cardiovascular diseases and the prognosis of chronic kidney disease].
Milovanova LY; Milovanov YS; Kudryavtseva DV; Markina MM; Milovanova SY; Kozlovskaya LV; Lebedeva MV; Beketov VD; Moiseev SV; Mukhin NA; Fomin VV; Svistunov AA
Ter Arkh; 2015; 87(6):10-16. PubMed ID: 26281189
[TBL] [Abstract][Full Text] [Related]
4. [MORPHOGENETIC PROTEINS--FIBROBLAST GROWTH FACTOR AND KLOTHO, IN THE SERA OF PATIENTS WITH CHRONIC RENAL DISEASE].
Milovanova LY; Kozlovskaya LV; Markina MM; Milovanova SY; Borisov AA; Mukhin NA; Fomin VV; Moiseev SV
Klin Med (Mosk); 2015; 93(12):32-8. PubMed ID: 27149811
[TBL] [Abstract][Full Text] [Related]
5. [New markers of cardio-renal links in chronic kidney disease].
Milovanova LIu; Milovanov IuS; Kozlovskaia LV; Mukhin NA
Ter Arkh; 2013; 85(6):17-24. PubMed ID: 23866594
[TBL] [Abstract][Full Text] [Related]
6. [Impact of anemia correction on the production of the circulating morphogenetic protein α-Klotho in patients with Stages 3B-4 chronic kidney disease: A new direction of cardionephroprotection].
Milovanov YS; Mukhin NA; Kozlovskaya LV; Milovanova SY; Markina MM
Ter Arkh; 2016; 88(6):21-25. PubMed ID: 27296257
[TBL] [Abstract][Full Text] [Related]
7. [Significance of the morphogenetic proteins FGF-23 and Klotho as predictors of prognosis of chronic kidney disease].
Milovanova LIu; Milovanov IuS; Kozlovskaia LV; Mukhin NA
Ter Arkh; 2014; 86(4):36-44. PubMed ID: 24864466
[TBL] [Abstract][Full Text] [Related]
8. The association between soluble klotho and cardiovascular parameters in chronic kidney disease: results from the KNOW-CKD study.
Kim HJ; Kang E; Oh YK; Kim YH; Han SH; Yoo TH; Chae DW; Lee J; Ahn C; Oh KH
BMC Nephrol; 2018 Mar; 19(1):51. PubMed ID: 29506503
[TBL] [Abstract][Full Text] [Related]
9. Reduction of Oxidative Stress in Chronic Kidney Disease Does Not Increase Circulating α-Klotho Concentrations.
Adema AY; van Ittersum FJ; Hoenderop JG; de Borst MH; Nanayakkara PW; Ter Wee PM; Heijboer AC; Vervloet MG;
PLoS One; 2016; 11(1):e0144121. PubMed ID: 26807718
[TBL] [Abstract][Full Text] [Related]
10. Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study.
Pavik I; Jaeger P; Ebner L; Wagner CA; Petzold K; Spichtig D; Poster D; Wüthrich RP; Russmann S; Serra AL
Nephrol Dial Transplant; 2013 Feb; 28(2):352-9. PubMed ID: 23129826
[TBL] [Abstract][Full Text] [Related]
11. Serum levels of soluble secreted α-Klotho are decreased in the early stages of chronic kidney disease, making it a probable novel biomarker for early diagnosis.
Shimamura Y; Hamada K; Inoue K; Ogata K; Ishihara M; Kagawa T; Inoue M; Fujimoto S; Ikebe M; Yuasa K; Yamanaka S; Sugiura T; Terada Y
Clin Exp Nephrol; 2012 Oct; 16(5):722-9. PubMed ID: 22457086
[TBL] [Abstract][Full Text] [Related]
12. Circulating α-klotho levels in CKD and relationship to progression.
Kim HR; Nam BY; Kim DW; Kang MW; Han JH; Lee MJ; Shin DH; Doh FM; Koo HM; Ko KI; Kim CH; Oh HJ; Yoo TH; Kang SW; Han DS; Han SH
Am J Kidney Dis; 2013 Jun; 61(6):899-909. PubMed ID: 23540260
[TBL] [Abstract][Full Text] [Related]
13. A decreased level of serum soluble Klotho is an independent biomarker associated with arterial stiffness in patients with chronic kidney disease.
Kitagawa M; Sugiyama H; Morinaga H; Inoue T; Takiue K; Ogawa A; Yamanari T; Kikumoto Y; Uchida HA; Kitamura S; Maeshima Y; Nakamura K; Ito H; Makino H
PLoS One; 2013; 8(2):e56695. PubMed ID: 23431388
[TBL] [Abstract][Full Text] [Related]
14. [Low serum Klotho level as a predictor of calcification of the heart and blood vessels in patients with CKD stages 2-5D].
Milovanova LY; Lysenko Kozlovskaya LV; Milovanova SY; Taranova MV; Kozlov VV; Reshetnikov VA; Lebedeva MV; Androsova TV; Zubacheva DO; Chebotareva NV
Ter Arkh; 2020 Jul; 92(6):37-45. PubMed ID: 33346491
[TBL] [Abstract][Full Text] [Related]
15. Plasma s-Klotho is related to kidney function and predicts adverse renal outcomes in patients with advanced chronic kidney disease.
Liu QF; Ye JM; Yu LX; He AL; Sun Q; He DW; Li SS
J Investig Med; 2018 Mar; 66(3):669-675. PubMed ID: 29061648
[TBL] [Abstract][Full Text] [Related]
16. Serum level of soluble (pro)renin receptor is modulated in chronic kidney disease.
Hamada K; Taniguchi Y; Shimamura Y; Inoue K; Ogata K; Ishihara M; Horino T; Fujimoto S; Ohguro T; Yoshimoto Y; Ikebe M; Yuasa K; Hoshino E; Iiyama T; Ichihara A; Terada Y
Clin Exp Nephrol; 2013 Dec; 17(6):848-56. PubMed ID: 23564382
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of fibroblast growth factor-23 and soluble alpha klotho in different stages of chronic kidney disease.
Khodeir SA; Okda HI; Abdalal HM
Saudi J Kidney Dis Transpl; 2019; 30(1):108-118. PubMed ID: 30804272
[TBL] [Abstract][Full Text] [Related]
18. The FGF23-Klotho axis and cardiac tissue Doppler imaging in pediatric chronic kidney disease-a prospective cohort study.
Tranæus Lindblad Y; Olauson H; Vavilis G; Hammar U; Herthelius M; Axelsson J; Bárány P
Pediatr Nephrol; 2018 Jan; 33(1):147-157. PubMed ID: 28795324
[TBL] [Abstract][Full Text] [Related]
19. [Effects of keto/amino acids and a low-protein diet on the nutritional status of patients with Stages 3B-4 chronic kidney disease].
Milovanova SY; Milovanov YS; Taranova MV; Dobrosmyslov IA
Ter Arkh; 2017; 89(6):30-33. PubMed ID: 28745686
[TBL] [Abstract][Full Text] [Related]
20. Renoprotective Effect of the Combination of Renin-angiotensin System Inhibitor and Calcium Channel Blocker in Patients with Hypertension and Chronic Kidney Disease.
Huang RS; Cheng YM; Zeng XX; Kim S; Fu P
Chin Med J (Engl); 2016 Mar; 129(5):562-9. PubMed ID: 26904991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
